nach oben

Clinical and Translational Oncology

Erschienen in:

01.12.2013 | Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013

verfasst von: A. Redondo, J. Cruz, A. Lopez-Pousa, F. Barón

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

The diagnosis and treatment of osteosarcoma should be performed by an experienced multidisciplinary team. Considering it is a systemic disease, chemotherapy is essential for long-term success. The drugs most commonly used are: cisplatin, adriamycin, high-dose methotrexate, ifosfamide, etoposide, and, more recently, mifamurtide. The neoadjuvant chemotherapy allows to know tumour chemosensitivity and getting the main prognostic factor: the percentage of tumour necrosis. In addition to chemotherapy, it is important to conduct surgical resection of primary tumour with wide margins, and in disseminated disease also to attempt resection of pulmonary metastasis.

Nur mit Berechtigung zugänglich

Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–43.PubMedCrossRef

Wittig JC, Bickels J, Prebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed

Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980;153:106–20.PubMed

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMedCrossRef

Hogerndoorn PCW. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;5:v204–13.CrossRef

Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–6.PubMedCrossRef

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival––a report from the children’s oncology group. J Clin Oncol. 2008;26(4):633–8.PubMedCrossRef

Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in non-metastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30(17):2112–8.PubMedCrossRef

Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72(11):3227–38.PubMedCrossRef

10.

Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6(2):329–37.PubMed

11.

Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415.PubMedCrossRef

12.

Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef

13.

Mineo TC, Ambrogi V, Pompeo E, Nofroni I. The value of the Nd:YAG laser for the surgery of lung metastases in a randomized trial. Chest. 1998;113:1402–7.PubMedCrossRef

14.

Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French society of paediatric oncology. Eur J Can. 1997;33(2):232–7.CrossRef

15.

Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419–25.PubMedCrossRef

16.

Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a paediatric oncology group phase II study. J Clin Oncol. 2001;19:3463–9.PubMed

17.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78–84.PubMedCrossRef

18.

Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and un resectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study. Ann Oncol. 2012;23(2):508–16.PubMedCrossRef

19.

Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K, et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. J Clin Oncol. 1999;17:1164–74.PubMed

Titel: SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013
verfasst von: A. Redondo
J. Cruz
A. Lopez-Pousa
F. Barón
Publikationsdatum: 01.12.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1087-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013

Abstract

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013

SEOM Guidelines 2013: a response to the needs of Spanish oncologists

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie